Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

NASDAQLPCN
FormDescriptionDateFormat
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Apr 29, 2016View HTMLDownload DOCDownload PDFDownload XLS
DEFA14AAdditional proxy soliciting materials - definitiveApr 29, 2016View HTMLDownload DOCDownload PDFDownload XLS